Netherlands-based ScreenPoint Medical has raised $14 million from existing investors Insight Partners and Siemens Healthineers, alongside $2 million in non-dilutive research grants, to scale its AI-powered breast cancer detection and risk assessment platform. The company’s Transpara Breast AI is deployed in over 30 countries with more than 12 million mammograms processed to date.
The funding comes alongside a significant body of new clinical evidence. The MASAI trial – the first randomized controlled trial of AI in breast cancer screening – published its final results in The Lancet, finding consistently favorable outcomes compared with standard double reading, including significant improvements in cancer detection and workload reduction. Separate prospective research published in Nature Medicine demonstrated that Transpara can safely reduce screening mammography workload by up to 63.6% by excluding low-risk mammograms from radiologist readings. And in npj Digital Medicine, ScreenPoint’s image-based breast cancer risk algorithm outperformed other solutions including Mirai, iCAD, and Google at five-year risk prediction – within the highest 14% of risk scores, the algorithm predicted 41.8% of all future cancers and 50.3% of interval cancers.
“We are well positioned to scale globally and accelerate the development of solutions that make care personal and powerful,” said CEO Pieter Kroese. “Our goal is to support clinicians and women across the full continuum of breast cancer care.”
“Our continued investment reflects our strong conviction that AI will play a defining role in the future of breast imaging,” said Alexandra Krumbügel, head of product line Women’s Health, X-ray Products at Siemens Healthineers.
The funding will support continued product innovation, international expansion, and strategic initiatives across the breast cancer care continuum – from prevention and screening to treatment.
